Construction of a recombinant B-cell epitope vaccine based on a Der p1-derived hypoallergen: a bioinformatics approach. (23rd March 2018)

• Record Type: Journal Article
• Authors: Fanuel, Songwe; Tabesh, Saeideh; Mokhtarian, Kobra; Saroddiny, Esmaeil; Fazlollahi, Mohammad Reza; Pourpak, Zahra; Falak, Reza; Kardar, Gholam Ali
• Is Part Of: Immunotherapy. Volume 10:Number 7(2018)
• Page Start: 537
• Page End: 553
• Publication Date: 2018-03-23
• Subjects: allergen-specific immunotherapy -- allergy -- Der p 1 -- epitopes -- house dust mite -- tetanus toxoid; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2017-0163
• Languages: English
• ISSNs: 1750-743X

Abstract

Aim: House dust mite (HDM) allergens are important elicitors of IgE-mediated allergies. This study was aimed at constructing and characterizing a recombinant fusion protein, DpTTDp, which was based on carrier-bound Der p 1-derived peptides for HDM allergen immunotherapy.Methods: Using the Immune Epitope Database (IEDB), we identified from Der p 1, a 34-mer hypoallergenic peptide. Two copies of the hypoallergen were then fused to a partial fragment of a tetanus toxoid molecule's N-and C terminus and expressed in Escherichia coli. After purification to homogeneity, the protein was evaluated for allergenicity and its ability to induce blocking antibodies upon immunization.Results: Upon immunization of mice, DpTTDp induced high levels of protective IgG-antibodies that blocked allergic patients' IgE reactivity to HDM. In addition, DpTTDp lacked relevant IgE-reactivity, induced low T-cell proliferation and IFN-γ in peripheral blood mononuclear cells of HDM-allergic patients' sera.Conclusion: The protein represents a promising HDM-allergy immunotherapy candidate vaccine.